BMY » Topics » Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

This excerpt taken from the BMY 8-K filed Nov 27, 2006.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On November 22, 2006, Bristol-Myers Squibb Company (the “Company”) issued €500,000,000 aggregate principal amount of its 4.375% Notes due 2016 (the “2016 Notes”) and €500,000,000 aggregate principal amount of its 4.625% Notes due 2021 (the “2021 Notes” and, together with the 2016 Notes, the “Notes”). Under their terms, the 2016 Notes bear interest at a rate of 4.375% per year and the 2021 Notes bear interest at a rate of 4.625% per year. The Company will pay interest on the Notes annually on each November 15, beginning November 15, 2007. The 2016 Notes will mature on November 15, 2016 and the 2021 Notes will mature on November 15, 2021. The Notes are unsecured and rank equally with all of the Company’s existing and future unsecured senior indebtedness. The Notes contain certain customary events of default and covenants, including limitations on consolidation, mergers, and sales of assets, limitations on the incurrence of certain liens, and limitations on certain sale and leaseback transactions. The Notes were issued in reliance on exemptions from the registration requirements of the Securities Act of 1933, as amended.

The above description of the Notes is qualified in its entirety by reference to the terms of the 2016 Notes and 2021 Notes, forms of which are attached as Exhibits 4t and 4u, respectively, and incorporated herein by reference.

This excerpt taken from the BMY 8-K filed Dec 14, 2005.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

On December 14, 2005, Bristol-Myers Squibb Company (the “Company”), through a wholly-owned subsidiary, borrowed an additional $500 million against its existing $2.5 billion term loan facility. The discussion contained under Item 1.01 of the Company’s Form 8-K filed August 11, 2005 is incorporated herein by reference.


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BRISTOL-MYERS SQUIBB COMPANY
Dated: December 14, 2005   By:  

/s/ Sandra Leung


    Name:   Sandra Leung
    Title:   Secretary
This excerpt taken from the BMY 8-K filed Nov 4, 2005.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

As previously reported on Form 10-Q for the period ended September 30, 2005, on October 27, 2005, Bristol-Myers Squibb Company (the “Company”), through a wholly-owned subsidiary, borrowed $2.0 billion against its existing $2.5 billion term loan facility. The discussion contained under Item 1.01 of the Company’s Form 8-K filed August 11, 2005 is incorporated herein by reference.


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BRISTOL-MYERS SQUIBB COMPANY
Dated: November 4, 2005   By:  

/s/ Sandra Leung


    Name:   Sandra Leung
    Title:   Secretary
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki